Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Ohio for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Ohio only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Ohio (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Antoine Chahine (NPI 1205879491)

Field	Value
Entity Type	Individual
Organization	Antoine Chahine
Address	3695a Boardman Canfield Rd
City	Canfield
State	OH
ZIP	44406
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	June 14, 2006

Payer Source	Total Paid
Medicare	$1.8M
Medicaid	$0

Key Findings

ANTOINE CHAHINE’s billing profile is consistent with an infusion-focused hematology/oncology practice: the top single code is J9271 (pembrolizumab) with $632K revenue (35.8% of this provider's total Medicare revenue), and the broader CPT mix includes chemotherapy administration codes (96413, 96417, 96415), supportive biologics (J2506, J0897), and infusion-related E/M and infusion administration codes. This mix indicates routine delivery of high-cost oncology infusions and related outpatient management rather than a primarily consultative or procedure-only practice.

Revenue is highly concentrated in a few Medicare codes: the precomputed top 3 Medicare codes by revenue account for 63.9% of this provider's total Medicare revenue, driven chiefly by J9271 (35.8%), J0897 (15.7%), and J1568 (12.4%). That concentration implies the practice’s financial performance is materially dependent on a small set of infused biologics and specialty products.

This provider is effectively single-payer in the available data: total Medicare revenue is $1.8M while Medicaid shows none on file, so Medicare accounts for essentially all reported public-payer billing. The absence of Medicaid billing on file means analysts should treat Medicaid as non-participation or non-billing in this dataset rather than a minor revenue source.

Competitive standing across individual drugs is mixed: J0897 (denosumab) shows notably strong national presence at rank #252 of 10057 providers nationally (97th percentile; notably above typical national volume for this code), and J1568 (IVIG, octagam) ranks #27 of 381 providers nationally (93th percentile; typical, unremarkable volume for this code). By contrast, J9271 (pembrolizumab) ranks #628 of 1841 providers nationally (65th percentile; typical, unremarkable volume for this code), indicating the practice is a high-volume outlier for some supportive biologics but a more typical participant for first‑line immunotherapy billing.

Office visit and outpatient E/M volume is unusually high relative to peers: 99213 accounts for 1.9K claims and $115.9K revenue (6.6% of Medicare revenue) and is flagged as an "extreme outlier, far above typical national volume" (rank #1070 of 457151 providers nationally, 100th percentile). This level of low‑complexity E/M billing alongside infusion services suggests steady clinic throughput and frequent follow-up visits for established patients.

Supportive care and infusion-related services show multiple above-typical national rankings, reinforcing the infusion-operational model: J2506 (pegfilgrastim) is #26 of 586 providers nationally (96th percentile; notably above typical national volume), 96375 is #172 of 5191 (97th percentile; notably above typical national volume), and 96413 is #377 of 7514 (95th percentile; notably above typical national volume). These elevated percentiles for supportive drugs and infusion administration codes indicate robust delivery of chemotherapy support and sequential infusion services.

Laboratory and monitoring codes are routine but relatively concentrated in volume for an oncology practice: 80053 (CMP) and 85025 (CBC) each generate roughly $17.1K and $14.4K in revenue respectively and rank in high percentiles (#762 of 26416 for 80053 at 97th percentile; #1141 of 32833 for 85025 at 97th percentile). The presence of frequent lab panels and tumor marker tests (82378, 86300) is consistent with active oncology care requiring ongoing monitoring.

Provider tenure is long-established: the NPI was enumerated on 2006-06-14 (~20 years ago), indicating sustained participation in Medicare over multiple reimbursement cycles. For payers and network planners, that tenure combined with a Medicare-dominant revenue base and no Medicaid billing on file suggests this clinician is an experienced Medicare-serving oncology clinician with concentrated infusion/service-line risk to a few high-revenue biologics.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

46 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	15,800	$40	$632K
J0897	Injection, denosumab, 1 mg	21,360	$10	$277.7K
J1568	Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg	10,420	$20	$218.8K
J1437	Injection, ferric derisomaltose, 10 mg	7,800	$20	$132.6K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	1,870	$60	$115.9K
J1454	Injection, fosnetupitant 235 mg and palonosetron 0.25 mg	180	$340	$60.3K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	620	$90	$58.7K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	1,080	$50	$52.9K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	21,000	$1	$42K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	240	$80	$19K

Showing 1–10 of 46

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 46 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Ohio Distribution

Antoine Chahine — 13 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Ohio

Full comparison — all codes billed, vs. state median

46 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	12	40	12,100	$40	$603K
J1568	1	10	3,840	$30	$128.3K
J0897	4	230	2,880	$20	$79.5K
J2506	2	10	480	$80	$49.8K
J0881	4	20	14,800	$1	$36.6K
J1437	1	20	1,700	$20	$34.9K
J1454	1	10	70	$340	$31.6K
80053	23	520	100	$10	$19.6K
96413	6	210	130	$90	$16.8K
86300	4	10	160	$20	$11.8K

Showing 1–10 of 46

Related Providers

Other providers that share a Tax Identification Number (TIN) with Antoine Chahine, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
John Graham	OH	Hematology & Oncology Physician	$427.3K	$0
Vaibhav Verma	OH	Hematology & Oncology Physician	$86.7K	$0

Nearby Providers

Other providers in the same ZIP code as Antoine Chahine, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Legacy Visiting Health Services	OH	Home Health Agency	$0	$27M
All Caring Hospice, LLC	OH	Community Based Hospice Care Agency	$0	$11.9M
Infusion Partners, LLC	OH	Home Infusion Therapy Pharmacy	$0	$7.5M
Nabila Sargious	OH	Specialist	$67.5K	$300.4K
Michael Derosa	OH	Endocrinology, Diabetes & Metabolism Physician	$173.3K	$0
Joseph Barak	OH	Foot & Ankle Surgery Podiatrist	$127.4K	$0
Stephen Brasko	OH	Physical Therapist	$125.4K	$0
Elizabeth Zinni	OH	Family Nurse Practitioner	$52.3K	$0
James Esperon	OH	Psychologist	$13.2K	$0
Daniel Garritano	OH	Plastic and Reconstructive Surgery Physician	$4.7K	$0

Antoine Chahine — Billing Profile & Reimbursement Data

Sign up for Antoine Chahine — Billing Profile & Reimbursement Data policy alerts

Antoine Chahine — Billing Profile & Reimbursement Data

Sign up for Antoine Chahine — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References